Glenmark to sell Shasun drugs in US
March 28, 2005 Glenmark Pharmaceuticals has entered into an agreement with Shasun for joint development, filing and marketing of 12 generic drugs for the US market. The product list consists of off-patent and patent protected molecules with cumulative annual sales of $8 billion in the US, Glenmark’s chief executive and managing director Glenn Saldanha said […]